There is evidence from studies in both animals humans which supports the theory of mesolimbic s persensitivity. In animal pharmacologic studies CN tolerance to neuroleptic effect is well documented, a prolonged exposure to neuroleptics leads to increas dosage requirements to block the behavioral effects, apomorphine (4, 5) . Muller and Seeman (6) reported increase of dopamine-binding sites not only in the ne striatum but also in the mesolimbic region of ra chronically treated with neuroleptics. In human stu ies, Owen and associates (7) showed an increase gf DA-binding sites in the mesolimbic region of s chiz 9; phrenic patients; this increase was related to the lengtH of treatment with neuroleptics. Recently, Lee and a' §2 sociates (8) also reported an increase of DA-bindiri: sites in the brains of schizophrenics.t
In an earlier paper, we presented evidence from t;Y9 double-blind controlled studies that suggests the exit ence-of this neuroleptic-induced supersensitivity di' s order (3) . In the present paper, we describe 10 cases'6 the disorder that illustrate the pharmacologic ali'
clinical characteristics of the syndrome, which, lit ardive dyskinesia, is a supersensitivity syndrome 1m
duced by long-term use of neuroleptic drugs. It consist of positive symptoms of schizophrenia, e.g., sus[ ciousness, delusions, or hallucinations, and does n'" include negative symptoms of the illness, e.g., em tional withdrawal or blunted affect. Like tardive dys' nesia, the supersensitivity psychosis has pharmacolo ic characteristics, described below, that are assoCi ed with its etiology of postsynaptic DA recep' supersensitivity. 1. Symptoms appear when neuroleptics are dis tinued, when dosage is decreased, or, in the case depot neuroleptics, at the end of the injection inter~, 2. The syndrome is associated with a history 0 least a few weeks of treatment with neuroleptics.;u 3. There are concomitant signs of DA su sensitivity (tardive dyskinesia) other than psychosis 4. The syndrome is associated with high prohi~f levels that result from the requirement for incrdl:se DA blocking to control psychotic symptoms indUt by the DA supersensitivity. The high prolactin ldiũ sually lead to signs of sexual dysfunction. . 'jf 5. There is also an association with CNS toletah to antipsychotic effect, Le., a gradual increase'I neuroleptic dosage is necessary to maintain a th€r peutic effect. D opamine (DA) receptor binding sites have been shown to increase in the neostriatum after chronic treatment with neuroleptics, and this could account for the DA supersensitivity that induces tardive dyskinesia (1). We have propposed that similar changes occur in the mesolimbic pathway in response to the chronic DA blockade by these drugs (2, 3) and that psychotic symptoms following withdrawal or decrease of neuroleptics could be the clinical expression of a mesolimbic DA postsynaptic receptor supersensitivity. According to this hypothesis, the cessation of maintenance neuroleptic medication induces a relative increase in the mesolimbic DA function, leading to psychotic relapse or deterioration in the same manner as tardive dyskinesia can emerge or worsen when medication is stopped or decreased. We have proposed the term "supersensitivity psychosis" for this ,phenomenon (3). swere under better control, except for the last 4 days ore the injections; these feelings were not associated with increase in his parkinsonian signs or symptoms, which ually improved toward the end of the injection interval. In ms of negative symptoms of schizophrenia-, Mr. A had mild emotional withdrawal that did not increase toward end of the injection interval. He was able to continue in 'occupation and normal way of life, but paranoid ideation urred a few days before each injection. This continued 6 months and necessitati::d the following dosage increas-_,: 12.5 mg every 2 weeks; 6 months later 25 mg every 2 eeks; 2 months later 37.5 mg every week; 6 months later 50 '.', every week. Over the next year, the pre-injection per-'utcry delusions and auditory haHucinations increased to h an extent that the patient was given fluphenazine enan- ' aJ dysfunction scale of 6 items. His prolactin level at me, 7 days after the injection, was 64 ng/ml, and he d positive and negative symptoms. In contrast,S days 'he injection, there were no positive symptoms or dys-GUY CHOUINARD AND BARRY D. JONES 17 kinetic movements, but his negative symptoms remained unchanged and his prolactin level was 94 ng/ml.
Case 2. Mr. B had been employed until his first psychiatric hospitalization, at the age of34. Over the previous 4 years he had had an insidious onset of persecutory delusions. On admission he was noted to have auditory hallucinations of people whom he believed to be gangsters laughing at him, talking about him in his room, and foHowing him on the street. Mr. B had no history of alcohol or drug abuse, and there was no family history of psychiatric iHness. He was discharged on chlorpromazine, 100 mg q.i.d., and remained stable for 10 years, during which time he had mild negative symptoms consisting of blunted affect, poverty of thought, and apathy with only mild and occasional exacerbation of persecutory delusions. However, 12 years after his initial hospitalization he experienced a relapse characterized by a belief that the Mafia was out to get him and had entered his house. He was then treated with chlorpromazine, 400 mg b.i.d., and fluphenazine enanthate, 25 mg LM. every 2 weeks. This was changed soon after to fluphenazine enanthate, 50 mg LM. every 2 weeks and chlorpromaziJ1e, 400 mg/day, at which point he was stable. However 2 months later he had a mild exacerbation, missed an injection, and deteriorated further. After receiving his regular injection he again stabilized, but (3 months later) he missed another injection and again deteriorated; he heard voices and felt unable to leave his house for fear of being killed. At this point his medication was increased to fluphenazine enanthate, 75 mg every 2 weeks, and chlorpromazine, 600 mg/day. He remained stable for 2 months but then deteriorated immediately after his chlorpromazine dosage was decreased. With an increase of fluphenazine enanthate to 100 mg every 2 weeks and chlorpromazine to 600 mg/day, Mr. B improved. The injectiOn was again increased to 125 mg but soon after this the patient missed an injection and quickly deteriorated. At this point, he also complained of persecutory delusions near the end of the injection interval, with no change in negative symptoms. The delusions were not associated with exacerbation of parkinsonian signs or symptoms such as akathisia. In fact, his parkinsonian symptoms improved toward the end of the injection interval. After 3 months on this regime, Mr. B's medication was changed to fluphenazine enanthate, 150 mg every 2 weeks. He remained stable for the next 11 months, at which point he again experienced marked persecutory delusions over the 4 days before his next injection. Therefore he was placed on fluphenazine enanthate, 100 mg per week. He remained stable for 4 months, when he missed an injection and subsequently deteriorated. An attempt was made to return him to 2~week injection intervals. He remained stable until a further attempt to decrease the dose from 100 mg to 87.5 mg resulted in an immediate relapse. After stabilization on a 100-mg dose, he was switched to fluphenazine decanoate, 200 rng every 4 weeks. Within 2 months he was again deteriorating over the last 4 days before his injection and the interval was changed to 3 weeks. He then remained stable for I month, when he began to deteriorate during the week before his injection. He was therefore returned 'to f1uphenazineenanthate, 100 mg every 2 weeks, and has since received increases of his injection to control recurring relapses near the end of the injection interval. At present Mr. B is receiving 175 mg of fluphenazine enanthate every 2 weeks. On this dose his prolactin level 2 weeks after the injectiori, at which time persecutory delusions and nega-"Prolactin levels and tardive dyskinesia scores were obtained immediately before the next injection of fluphenazine enanthate. "Patient also receiving fluphenazine decanoate; dose given is fluphenazine enanthate plus decanoate. 'Values not assessable .
•Patient receiving only fluphenazine decanoate.
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We have described the neuroleptic-induct supersensitivity psychosis and its seven charaet~r.
istics. These characteristics are necessary to establ'" the existence of the supersensitivity disorder. The',.
.'.w ith psychotic decompensation. All patients describe in table 1 have shown the most characteristic featuf of the syndrome, a relapse manifested by an increas' in positive symptoms immediately after decreases iq neuroleptic dosage. In contrast, negative symptomsjt hese patients, as in the two patients desciibedp'~.
viously, did not increase in the same circumstanceS
The syndrome is associated with an elevated pI' lactin level that usually leads to sexual dysfunctio Male patients tended to have a smaller prolactin elev tion than female patients, but their levels are above t' . . ceived their injections and are conservative estimates because neuroleptic blood levels are very low at tti~t time. The low scores for tardive dyskinesia seenjii some of these patients can be explained by the rag that they were receiving high doses of injectab!e neuroleptics, and some were receiving oral neurolep"' tics at the end of the injection interval, both of whi~. would cover the manifestations of tardive dyskinesiat;,.' ¥ ''I:';
10
Patient tive symptoms were present, was 25 ng!ml, and his rating for tardive dyskinesia on the. ESRS was 13, indicating moderate dyskinesia (abnormal movement of the tongue and lips and choreoathetoid movements of the lower extremities). In contrast, 5 days after the injection the prolactin level was 38 ng! ml, tardive dyskinesia and positive symptoms were absent, and negative symptoms were still present. Table 1 summarizes the data for these 2 patients and 8 others regarding neuroleptic doses over a 3-year period. All patients were diagnosed as schizophrenic. During this period they had been treated as outpatients in a special follow-up clinic for long-term treatment of schizophrenia. This clinic has an average patient population of 300 actively involved in treatment. The patients presented here are typical of those manifesting the supersensitivity psychosis and required a gradual increase in medication over time. However, this was not always so, as can be seen in the case ofMr. B .. Since the policy at the clinic is to give the minimum therapeutic dose, a reduction in the medication will be expected for those patients who will have a remission of their illness. However, the appearance of the neuroleptic-induced psychosis in the patients presented did .not permit complete withdrawal of the neuroleptic drug. Before adjusting a patient's neuroleptic dose, a full assessment of extrapyramidal signs and symptoms was always done to rule out the possibility of neuroleptic-induced extrapyramidal reactions associated :., .;
Other Cases
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'~ensitivity psychosis was defined as consisting only ftpositive symptoms of schizophrenia, in particular piciousness, delusions, ;and hallucinations. We e proposed that positive symptoms of schizophreiresult from a relative DA hyperactivity in the .olimbic region, whereas negative symptoms re-;from DA hypo activity (2) . Neuroleptic-induced rsensitivity in the mesolimbic region would thus pear clinically as an increased tendency toward pos-'e symptoms. This has been our experience with the s reported here. In contrast, negative symptoms, 'ch we have not seen in the psychotic decompensa-:that is contingent in these cases on drug decrease, :'jJ ..llnght be expected to improve over time on mainte-,J;'J>;""ce neuroleptic therapy because of DA super-'sitivity induction. This is consistent with our clini-/~,.lexperience that negative symptoms of schizophre-;I i ffH1i';improve only after a few weeks of neuroleptic dr::!;'-".j./,-:~; " .." rapy or when neuroleptlcs are Withdrawn. . The first characteristic of the syndrome is that it ap-;;"pears almost immediately after neuroleptics are dis-:~J)Iitinued or decreased. This is contrary to the normal ;~'i~'btirse of most forms of schizophrenia, in which thẽ iW~ess would not be expected to worsen upon dr.ug 41,wlthdrawal. In the cases we have reported the deteno-1I!fion is clearly evident when the neuroleptic dosage is .~~educed or the patient misses one or two injections. :.~"""b'se patients show a similar pattern of deterior~tion .h respect to the severity of their tardive dyskinesia. is is consistent with the proposed etiology of drug-'Ilced DA. supersensitivity for both the psychotic d: dyskinetic deterioration. In questioning patients ohave received maintenance neuroleptic treatment "~;!:lave developed mesolimbic supersensitivity, one '1s such statements as, "Before, I was not taking ::medication regularly and I was readmitted once a ". ,~fir' or every two years. Now since I take my medica-
)"'<<": regularly, I get sick as soon as I miss a single intion or stop taking my rpedication.' , The induced "fsupersensitivity will not be clinically evident in its chotic or dyskinetic symptom expression if it is red by the neuroleptics themselves. Thus the synrrie may be masked in patients who are receiving 'ded doses of oral neuroleptics. In the cases we deBed, all patients were receiving only long-acting inhie medication when the syndrome became eviJo us through psychotic decompensation late in Uection interval, a time when neuroleptic blood s would be expected to be low. However, the synemay also be seen in patients taking oral neuro-'s once a day. An example of this would be Mr. A el), who reported psychotic symptoms beginning :'afternoon when he was receiving only a single dose of oral neuroleptic at bedtime. We think 'is may also explain the discrepancy in the literagarding the incidence of tardive dyskinesia. The urveys of tardive dyskinesia, done when neurowere usually given in divided doses during the GUY CHOUINARD AND BARRY D. JONES ' 19 day, showed an incidence of less than 1%, whereas the latest surveys, taken since the single daily oral doses and injectable neuroleptics have become common, report an incidence of 30%-40% (11) . There is also evidence from one of our studies that patients treated with injectable neuroleptic's show an even higher incidence of tardive dyskinesia when rated at the end of the injection interval (10). The second characteristic is a history of consistent exposure to neuroleptics. Tardive dyskinesia is usually observed after several years of treatment; rare cases have been reported after 6 months. In our case 1, supersensitivity psychosis appeared after 6 months, whereas in the other cases it became clinically evident only after a number of years of neuroleptic treatment. However, the syndrome's clinical appearance varies according to the masking effect of neuroleptics or unmasking by a decrease of dosage.
The third characteristic is that other clinical signs of DA supersensitivity would be expected in patients who have developed supersensitivity psychosis. Animal and human studies show that DA supersensitivity develops to a similar degree in the neostriatum and mesolimbic region after exposure to neuroleptics that have approximately equal potency to block DA receptors in these areas (6, 7). Thus, tardive dyskinesia resulting from drug-induced neostriatum supersensitivity would be more prevalent and severe in patients manifesting supersensitivity psychosis .. In the cases reported, tardive dyskinesia was seen and, as mentioned previously, worsened when patients experienced psychotic deterioration as a result of decreased neuroleptic levels. Similarly, in a double-blind controlled study we found a tendency for psychotic deterioration to be associated with increased severity of tardive dyskinesia in patients withdrawn from their regular neuroleptic medication (3). It should be noted, however, that the clinical signs of DA supersensitivity can be covered by neuroleptics. Thus in patients whose psychotic symptoms are controlled by increases in the neuroleptic dose, the expression of tardive dyskinesia may be suppressed similarly. It should also be noted that the relationship between the two supersensitivity disorders may be obscured by the use of anticholinergic drugs that affect the clinical manifestation of tardive dyskinesia but not the supersensitivity psychosis (12) .
The fourth characteristic of the syndrome is its association with high prolactin levels, which may produce clinical signs of sexual dysfunction. Development of DA supersensitivity in the tubero-infundibulum has not been demonstrated, and our own studies do not suggest such supersensitivity (13). Thus if neuroleptic doses are increased to control. emerging psychotic symptoms in patients with supersensitivity psychosis, there will be progressive increases in DA-blocking activity in the tubero-infundibulum. These increases will be unopposed because of the lack of DA supersensi-sensitivity syndrome, as they are in tardive dys nesta.
The seventh characteristic of the syndrome is that may exist on a continuum, as is true in tardive dys nesia (9). The cases presented here illustrate the lat stages of the syndrome, in which ioe covert supers ensitivity psychosis is uncovered by a dosage redu2.)i tion and finally becomes apparent during neuroleptic treatment, necessitating further increases in dosag?; Thus, the need for neuroleptic therapy to control ths upersensitivity psychosis would be expected to~~, continual.:~:
In addition, one might speculate on one further chah acteristic of the supersensitivity psychosis syndrom~" schizophrenic patients may be more prone to develqQ , supersensitivity psychosis than nonschizophrenic pit tients. We have proposed that schizophrenia is a dopam ine deficiency disease and that the positive sympJ' toms of schizophrenia are due to postsynaptic recept6D
A supersensitivity resulting from this dopamine de ' ciency (2) . DA-blocking drugs are thus efficacious' controlling the symptoms of the supersensitivity ps chosis, as they are in masking tardive dyskine" symptoms. However, the DA-blocking effect of thes drugs, added to the existing DA deficiency, will lead t further development of dopaminergic supersensitivit in schizophrenic patients. This would be in contrast t nonschizophrenic patients, who do not have dopamirt deficiency as an original element of the disease an thus would be expected to have less tendency to deve' op dopaminergic supersensitivity in response to neur leptics. It has been our clinical experience that rna bipolar manic patients do not show signs of supes ensitivity psychosis on neuroleptic withdrawal ana have less tendency to develop tardive dyskinesia.rHe proneness of sChizophrenic patients to develop neur~.. leptic-induced dopaminergic supersensitivity in the mesolimbic region may be similar to the increased teq' dency in parkinsonian patients to develop dyskines! in response to L-dopa treatment (15) . However,t4 fact that animal studies show dopaminergic supf! sensitivity in the mesolimbic region, despite presi,!': ably normal preneuroleptic dopamine function,' stl gests that supersensitivity psychosis may not be cdn fined to schizophrenic patients. Finally" elderl patients and those for whom the neuroleptic has littJ' therapeutic effect might be more likely to develop'tB syndrome, just as they are more likely to develop"'" dive dyskinesia (II).
SUPERSENSITlVITY PSYCHOSIS 20 tivity development there. Prolactin, which is inhibited by dopamine, will then increase in such patients to levels that are in accord with the degree of DA-blocking needed to counteract mesolimbic DA supersensitivity. Thus patients who have developed supersensitivity psychosis would be expected to show abnormally elevated prolactin levels and sexual dysfunction. In the cases reported, elevated prolactin levels and symptoms of sexual dysfunction were present. Furthermort, we have found that patients who deteriorate when neuroleptics are withdrawn tend to have greater prolactin decreases than patients who remain stable (3) .
The fifth characteristic is that the syndrome is usually associated with eNS tolerance to antipsychotic effect, i.e., a gradual increase in neuroleptic dosage is necessary to maintain the therapeutic effect. In animal studies, this tolerance is well recognized (4, 5) . In addition, Bowers and Rozitis (14) have reported a tolerance to neuroleptic-induced increases in HVA concentration in the mesolimbic region. We also reported that during a 7-month double-blind controlled study with esters of fluphenazine (3), 44% of the patients required dosage increases. Of the cases presented here, case 1 is the best example of such a drug tolerance. We think that drug tolerance to antipsychotic effects will be seen most easily in outpatients who are employed in jobs that involve a certain amount of stress. Patients receiving long-term care in mental hospitals are less likely to display such tolerance because they are under minimal stress and have less need for medication. It might be argued that this is a metabolic drug tolerance and that measurements of blood levels therefore would be necessary. However, based on our experience with gas chromatography-mass spectrometry, we do not think that reliable measurements of fluphenazine levels can be made at this time. The unreliability of available methods results from the tendency of f1uphena-, zine to concentrate in the red blood cells. Further-" more, we think that prolactin measurements reflect the DA-blocking activity of neuroleptics and that their elevation with increasing drug dosage rules out a metabolic tolerance to neuroleptics. That such increases in neuroleptic dosage have not been noted previously in the literature probably results from the lack of longterm studies of patients receiving only one injectable neuroleptic and no other medications except antiparkinsonians. Only in this patient population will such variables as gastrointestinal absorption, liver metabolism, and patient compliance be controlled. The sixth characteristic of the syndrome is that the causative agent, the neuroleptic, is the most efficacious treatment, as is true in tardive dyskinesia. This is well demonstrated in the cases we have presented. Each time the neuroleptic medication was increased, the supersensitivity psychosis improved. We also think that the more potent neuroleptics with a strong DA-blocking effect are better suppressors ofthe super-.;
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